ClinicalTrials.gg
RecruitingNCT04599010Updated May 27, 2026

Role of Body Composition in Large for Gestational Age Infants (LGA) With Oral Feeding Difficulty

An interventional study of Dietary intervention in Body Composition, Feeding; Difficult, Newborn and Nutrition Disorder, Infant, sponsored by Nemours Children's Clinic. Recruiting at 2 sites in United States. Open to participants aged 1 Week to 10 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-27.

Sponsored by Nemours Children's Clinic · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 1 month later.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
1 Week to 10 Weeks
Sex
All
01

Study summary

Large for Gestational Age (LGA) infants have excess fat-mass (FM) proportion secondary to prolonged in utero exposure to an energy-rich environment. Our preliminary data suggest that excess FM proportion can be associated with oral feeding delay and a potentially modifiable therapeutic target to improve oral feeding outcomes. The objective of this study is to determine the impact of a short-term Fat-free mass (FFM)-indexed feeding on the oral intake volumes in LGA infants with oral feeding difficulties.

Read the detailed description

Eligible subjects will be randomized to an innovative FFM-indexed feeding or the standard feeding for up to 2 weeks. The essential component of the FFM-indexed feeding will be the difference in milk prescription dosing that we propose to set the feeding volume to index FFM rather than total mass. In FFM-indexed feeding, there will be a permissive feeding volume restriction to 150 ± 10 mL/kg (FFM)/day without increasing the milk calorie density or changing the type of formula milk, whereas the standard feeding will include a feeding volume goal of 150 ± 10 mL/kg (body weight)/day. Infants will receive either breast milk or formula feedings per the standard feeding protocols. Body composition (PEAPOD system) and appetite-regulating hormones (ARH) levels of enrolled infants will be assessed at baseline (test-1) and at the end 2-week study intervention period (test-2). Subjects will be followed for clinical and growth outcomes until neonatal intensive care unit (NICU) discharge and through 6 months of age. Growth will be followed through 6 months of age by retrieving anthropometric measurement records from pediatricians at well-child visits (2-, 4-, 6- and 6-month visits). Parents will be called at these time points to obtain a history of any further feeding difficulties.

02

Conditions studied

  • Body Composition
  • Feeding; Difficult, Newborn
  • Nutrition Disorder, Infant
03

In context

Infant Nutrition Disorders

67 studies on the registry are indexed under Infant Nutrition Disorders; 14 are open to participants now.

This study's planned enrollment of 40 is below the median of 180 across 46 interventional studies indexed under Infant Nutrition Disorders.

Browse Infant Nutrition Disorders studies →

Lead sponsor

Nemours Children's Clinic is the lead sponsor of 130 studies on the registry; 26 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Week to 10 Weeks
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • LGA infants with oral feeding difficulty born at ≥ 35 weeks gestation, with FM z-score > +1.0 in body composition measurement

Exclusion criteria

Exclusion Criteria:

  • Infants on any respiratory support, Infants on enteral feeding duration > 60 minutes due to hypoglycemia concerns, videofluoroscopic swallow study (VFSS) demonstrating unsafe swallowing function, GI surgical conditions, significant neurological morbidities, and major congenital, genetic syndromes/anomalies
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    FFM-indexed feeding

    In FFM-indexed feeding, there will be a permissive feeding volume restriction to 150 ± 10 mL/kg (FFM)/day without increasing the milk calorie density or changing the type of formula milk for 2 weeks in the intervention group

    Other: Dietary intervention

  • Active comparator
    Standard feeding

    The standard feeding approach will include an oral feeding volume goal of 150 ± 10 mL/kg/day during the 2-week study period

    Other: Dietary intervention

Interventions

  • OtherDietary intervention

    energy-restricted diet appropriate for resting metabolic rate using FFM as proxy

06

What researchers measure

Primary outcomes

  1. Time from study entry to independent oral feeding

    full oral feeding defined as 120 ml/kg/d without tube feeding for 2 consecutive days

    Time frame: Before or at NICU-discharge

Secondary outcomes

  1. oral feeding volume at NICU discharge

    oral feeding volume (mL/kg/day) at discharge

    Time frame: before 3 months

  2. NICU Feeding related length of stay (LOS)

    Days from first oral feeding to independent oral feeding

    Time frame: before 3 months

  3. Gastrostomy rates

    Percentage of infants with gastrostomy placement

    Time frame: through study completion, an average of 1 year

  4. ARH levels

    Directional changes in ARH pre-post intervention

    Time frame: 2 weeks

  5. Oral feeding success rate

    Independent oral feeding at NICU discharge

    Time frame: Before 3 months

  6. Body composition change in FM and FFM

    Directional changes in FM and FFM pre-post intervention

    Time frame: 2 weeks

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data requests can be submitted starting 9 months after article publication and the data will be made accessible for up to 24 months. Extensions will be considered on a case-by-case basis

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data requests can be submitted starting 9 months after article publication

Access criteria: Access to trial IPD can be requested by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA)

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Jul 2027, 34 months after the start.

Of 25 interventional studies with no phase under Infant Nutrition Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 27. This study's planned 34 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2020
First posted
Oct 22, 2020
StartActual
Sep 26, 2024
Primary completionEst.
Jul 31, 2027
CompletionEst.
Dec 31, 2027
Last update
May 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04599010
Collaborators
Emory University
Responsible party
Sreekanth Viswanathan (Attending Neonatologist, Professor of Pediatrics, Nemours Children's Clinic) — Principal investigator
First posted
Oct 22, 2020
Start date
Sep 26, 2024
Primary completion
Jul 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
May 27, 2026

Study contacts

Sreekanth Viswanathan, MD,MS
Contact
sreekanth.viswanathan@nemours.org
4076977603
Sreekanth Viswanathan, MD
principal investigator · Nemours Children's Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion